Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NewCardio Signs MSA With US CRO For QTinno
In addition, NewCardio has signed a services work order, including standard operating procedures (SOP) and validation kits, as well as professional services, in order to accelerate its readiness
In addition, NewCardio has signed a services work order, including standard operating procedures (SOP) and validation kits, as well as professional services, in order to accelerate its readiness
The BD Protect system, designed by CDC-trained epidemiologists, addresses multiple issues confronting healthcare administrators and public health officers, including the transmission of multidrug-resistant organisms in healthcare settings and
The new SphygmoCor offers improvements to simplify clinical use, and will assist evaluation of cardiovascular status and management of patient care by medical specialists, particularly cardiologists, hypertension specialists,
AssistMed’s Patient Adherence Solutions include Clinication, a web-based patient/provider adherence management system and CellPly, a device-independent mobile phone solution which follows the patient wherever they may be. The
The tool was developed by Harvard Catalyst, The Harvard Clinical and Translational Science Center, and was officially released to the open source community by Harvard University. Profiles Research
NextDocs is expected to provide software licenses and solutions to customers and Hitachi will provide supporting services including business consulting, system integration, training, operation and validation support for
The patent technology covers future iterations of the company’s SecondLook Digital Computer-Aided Detection (CAD) solution with potential application to the company’s other image analysis solutions. Ken Ferry, President
The proton therapy systems have been shown to tailor high-energy doses to attack cancerous tumors while minimizing damage to adjacent tissue, whereas conventional cancer treatment using high-energy x-rays
Under the agreement, LEO Pharma’s clinical expertise and Intomics technology in analyzing biological data will be combined to help the LEO Pharma quickly develop better and safer drugs.
PharPoint plans to utilise Medrio’s technology in all phases of clinical drug development from Phase I – IIIb studies as well as post marketing studies, registries and outcomes